DailyIQ
|
Sector:HealthcareAll sectors
Last updated3 minutes ago

HSIC·Henry Schein, Inc.

$89.81
-1.05 (-1.16%)
Market Closed (Overnight)$89.81+0.00 (+0.00%)
High
$90.90
Open
$89.95
Market Cap
10.09B
52W High
$92.18
Low
$89.64
P. Close
$89.81
P/E
25.03
52W Low
$60.30
Fwd P/E
15.04
DailyIQ Est.
$101.13
Inst. Ownership
45.6%
Short Interest
6.16%
Days to Cover
5.0
Technical Score (1D)
73
BUY
News Sentiment
63
BULLISH
Henry Schein’s latest earnings report, released 17.9 hours ago, showed a 15.5 % year‑over‑year rise in adjusted EPS to $1.27 and net sales of $3.46 billion, up 6.7 % and beating consensus estimates. The upside was driven by 4.6 % internal sales expansion, 0.7 % from acquisitions and 1.4 % foreign‑currency gains, with distribution and specialty product segments leading the charge. Because the company exceeded expectations, the market now views HSIC as a stronger growth play, which may attract new capital inflows and lift investor confidence over the next trading week. The Zacks upgrade to a top‑growth pick, announced 15.7 hours ago, reinforces this narrative by highlighting HSIC’s high growth score and above‑average financial expansion, further supporting a bullish stance for the near term. The combined effect of the earnings beat and the analyst endorsement suggests that HSIC’s valuation could tighten as traders anticipate continued momentum. Watch for the company’s next earnings release in the coming weeks to confirm whether the growth trajectory persists and whether any guidance revisions alter the outlook. Additionally, monitor any updates on the acquisition pipeline, as new deals could materially impact short‑term revenue and margin dynamics. Finally, keep an eye on broader healthcare‑products sector sentiment, as shifts in demand or regulatory changes could influence HSIC’s competitive positioning relative to peers.
Earnings Summary
Henry Schein, Inc. is a global distributor of healthcare products and services, primarily serving dental and medical practitioners with a broad portfolio that includes dental merchandise, equipment, pharmaceuticals, specialty products, practice management software, and educational resources, positioning it as a value‑added partner in the medical distribution sector. In the most recent quarters, the company posted revenue of $3.437 billion in Q4 2025 and $3.368 billion in Q1 2026, a slight decline from the $3.240 billion in Q1 2025 but an increase from the $3.240 billion in Q1 2025, reflecting a modest revenue acceleration in the second half of 2025 and a small dip in early 2026; EPS, however, rose from $1.10 in Q2 2025 to $1.38 in Q3 2025 and then to $1.34 in Q4 2025, indicating strong earnings momentum that outpaced revenue growth. The company has consistently beat analyst estimates in the last four quarters, with EPS exceeding forecasts in Q3 2025 and Q4 2025, while revenue growth has remained steady at around 3–4 % year‑over‑year. Historically, HSIC has maintained double‑digit revenue growth and EPS expansion, with a pattern of beating estimates even when revenue growth slows, underscoring disciplined cost management and recurring revenue streams. Recent news highlights a broad second‑quarter lift across all core segments—Global Distribution and Value‑Added Services up 6.6 %, Specialty Products up 8.7 %, and Technology up 8.2 %—which prompted management to raise its 2026 sales and earnings guidance; analysts have responded by lifting price targets, reflecting confidence in the company’s earnings outlook and steady demand in the medical supplies sector. Investors should watch the upcoming earnings release for any guidance on cost management and margin trends, as well as regulatory developments that could affect the dental supply chain, and monitor the pace of digital transformation initiatives to assess whether the upward price targets remain justified.

EPS

EstBeatMiss
$1.06$1.15$1.24$1.33$1.42Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.35 - -
Q2'26$1.26$1.27+0.7%
Q1'26$1.22$1.32+8.4%
Q4'25$1.26$1.34+6.3%
Q3'25$1.28$1.38+7.9%
Q2'25$1.19$1.10-7.6%

Revenue

EstBeatMiss
$3.2B$3.3B$3.4B$3.5B$3.6BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.5B - -
Q2'26$3.4B$3.5B+0.5%
Q1'26$3.4B$3.4B-0.2%
Q4'25$3.3B$3.4B+3.1%
Q3'25 - $3.3B -
Q2'25 - $3.2B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

HSIC Stock Snapshot

BUY73/100
$89.81+$0.00 (0.0%)
Market cap
10.09B
P/E ratio
25.0
Day range
$89.64 – $90.90
News sentiment
63/100 · Bullish
Analyst target
$98.19 (+9.3%)
Consensus
Hold · 26 analysts
52-week range+48.9% off low · -2.6% from high
$60.30$92.18
Price $89.81 DailyIQ Est. $101.13

HSIC's technical picture is constructive, with trend and momentum pointing the same direction. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into HSIC?

FAIR

At today's price, Henry Schein, Inc. needs to grow free cash flow about 3.9% a year for the next 10 years to justify its valuation at a 7.15% cost of capital. Over its actual history it has compounded free cash flow at 2.6% a year, so the market is asking for 1.3 percentage points above its own delivered rate. On that basis HSIC looks priced roughly in line with its own growth record.

Implied FCF growth
3.9%
Historical FCF CAGR
2.6%
Growth gap
+1.3 pts
Verdict
FAIR
Discount rate (WACC)
7.15%
Beta
0.68

Behaviour On Record

What HSIC's own history says about today's numbers

Realized volatility (21d)
16.8% 25th pct
Below its peak
-1.2%
vs 200-day average
+15.2%
Up days (1y)
51%

Henry Schein, Inc. is currently running 16.8% annualised volatility over the last 21 sessions. Measured against HSIC's own 13 years of daily returns rather than a market-wide average, that is the 25th percentile — on the quiet side for this stock, against a typical reading of 22.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

HSIC is trading -1.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -20.3%, and the deepest was -40.9% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +15.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 97th percentile — a wider gap than this stock usually carries. Over the past year HSIC closed higher on 51% of sessions, and it is currently 2 sessions into a rising streak.

On September specifically: over 13 years of records, HSIC finished the month higher 5 of 13 times, with a median return of -0.7% and an average of -1.3%. Its strongest month historically has been November at +4.7% on average, its weakest August at -3.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: HSIC has opened more than 2% away from the prior close in 111 of 3,267 sessions (3.4% of the time), with the largest gaps running +5.2% and -10.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, HSIC moved an average of 1.6% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.7% and a largest of -2.6%.

All figures computed from 3,269 daily closes between 2013-09-05 and 2026-09-03, split-adjusted, recomputed daily. Percentiles are against HSIC's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of HSIC's sector?

Henry Schein, Inc. sits in the Health Care sector, currently ranked 2nd of 11 GICS sectors by relative-strength rotation score (weakening).

Sector rank
#2 of 11
Sector state
Weakening
Sector rotation score
90

Options Market

What is the options market pricing for HSIC?

CallsPuts

For Henry Schein, Inc.'s nearest expiry (2026-09-18, 13 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.07), with at-the-money implied volatility around 40.5%. The options market is pricing roughly a ±8.7% move by that expiry — a range of about $81.95–$97.51.

Put/call ratio (2026-09-18)
0.07
ATM implied volatility
40.5%
Total open interest
145
Expected move by 2026-09-18
±8.7% ($81.95–$97.51)

HSIC Competitive Positioning

Henry Schein, Inc. (HSIC) is tracked alongside these names in Medical Distribution on DailyIQ — ranked by market cap, with today's move alongside.

Held by These ETFs

HSIC is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.